Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1966 1
1968 1
1969 2
1971 7
1972 4
1973 6
1974 4
1975 15
1976 8
1977 11
1978 1
1979 8
1980 7
1981 8
1982 15
1983 12
1984 14
1985 16
1986 27
1987 25
1988 17
1989 10
1990 15
1991 16
1992 12
1993 13
1994 20
1995 23
1996 18
1997 33
1998 26
1999 32
2000 36
2001 47
2002 61
2003 59
2004 73
2005 85
2006 107
2007 123
2008 146
2009 169
2010 159
2011 183
2012 224
2013 236
2014 279
2015 306
2016 310
2017 386
2018 447
2019 518
2020 593
2021 755
2022 817
2023 791
2024 749
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,260 results

Results by year

Filters applied: . Clear all
Page 1
The immune niche of the liver.
Cheng ML, Nakib D, Perciani CT, MacParland SA. Cheng ML, et al. Clin Sci (Lond). 2021 Oct 29;135(20):2445-2466. doi: 10.1042/CS20190654. Clin Sci (Lond). 2021. PMID: 34709406 Review.
Itaconate inhibits TET DNA dioxygenases to dampen inflammatory responses.
Chen LL, Morcelle C, Cheng ZL, Chen X, Xu Y, Gao Y, Song J, Li Z, Smith MD, Shi M, Zhu Y, Zhou N, Cheng M, He C, Liu KY, Lu G, Zhang L, Zhang C, Zhang J, Sun Y, Qi T, Lyu Y, Ren ZZ, Tan XM, Yin J, Lan F, Liu Y, Yang H, Qian M, Duan C, Chang X, Zhou Y, Shen L, Baldwin AS, Guan KL, Xiong Y, Ye D. Chen LL, et al. Among authors: cheng m. Nat Cell Biol. 2022 Mar;24(3):353-363. doi: 10.1038/s41556-022-00853-8. Epub 2022 Mar 7. Nat Cell Biol. 2022. PMID: 35256775 Free PMC article.
Sublethal necroptosis signaling promotes inflammation and liver cancer.
Vucur M, Ghallab A, Schneider AT, Adili A, Cheng M, Castoldi M, Singer MT, Büttner V, Keysberg LS, Küsgens L, Kohlhepp M, Görg B, Gallage S, Barragan Avila JE, Unger K, Kordes C, Leblond AL, Albrecht W, Loosen SH, Lohr C, Jördens MS, Babler A, Hayat S, Schumacher D, Koenen MT, Govaere O, Boekschoten MV, Jörs S, Villacorta-Martin C, Mazzaferro V, Llovet JM, Weiskirchen R, Kather JN, Starlinger P, Trauner M, Luedde M, Heij LR, Neumann UP, Keitel V, Bode JG, Schneider RK, Tacke F, Levkau B, Lammers T, Fluegen G, Alexandrov T, Collins AL, Nelson G, Oakley F, Mann DA, Roderburg C, Longerich T, Weber A, Villanueva A, Samson AL, Murphy JM, Kramann R, Geisler F, Costa IG, Hengstler JG, Heikenwalder M, Luedde T. Vucur M, et al. Among authors: cheng m. Immunity. 2023 Jul 11;56(7):1578-1595.e8. doi: 10.1016/j.immuni.2023.05.017. Epub 2023 Jun 16. Immunity. 2023. PMID: 37329888 Free article.
Reply.
Teo KYC, Kokame G, Sadda SR, Fujimoto S, Gomi F, Kim JE, Cheng MFS, Corradetti G, Amornpetchsathaporn A, Chainakul M, Lee WK, Lai TYY, Ruamviboonsuk P, Cheung CMG. Teo KYC, et al. Among authors: cheng mfs. Ophthalmol Retina. 2023 Jul;7(7):e10-e11. doi: 10.1016/j.oret.2023.03.013. Epub 2023 Apr 20. Ophthalmol Retina. 2023. PMID: 37086256 No abstract available.
Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer.
Zhu Y, Zhao Y, Wen J, Liu S, Huang T, Hatial I, Peng X, Al Janabi H, Huang G, Mittlesteadt J, Cheng M, Bhardwaj A, Ashfeld BL, Kao KR, Maeda DY, Dai X, Wiest O, Blagg BSJ, Lu X, Cheng L, Wan J, Lu X. Zhu Y, et al. Among authors: cheng m. Sci Immunol. 2023 Mar 17;8(81):eade4656. doi: 10.1126/sciimmunol.ade4656. Epub 2023 Mar 10. Sci Immunol. 2023. PMID: 36897957 Free PMC article.
Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial.
Zhang L, Wu ZY, Li J, Lin Y, Liu Z, Cao Y, Zhang G, Gao HF, Yang M, Yang CQ, Zhu T, Cheng MY, Ji F, Li J, Wang K. Zhang L, et al. Among authors: cheng my. Int J Cancer. 2022 Feb 15;150(4):654-662. doi: 10.1002/ijc.33830. Epub 2021 Oct 7. Int J Cancer. 2022. PMID: 34591977 Clinical Trial.
7,260 results